Always Remember - Buy The Dip

Sentiment Analysis For MRNS

The news is currently generally neutral for MRNS.

Based on TextBlob analysis of Yahoo! Finance news summaries for MRNS on 2015-04-30.

Yahoo! Finance News for MRNS

Marinus Pharma: FDA Grants Orphan Drug Designation For Ganaxolone - Quick Facts
Marinus Pharma: FDA Grants Orphan Drug Designation For Ganaxolone - Quick Facts

AVGR Working Towards Vision, MRNS On Track, CCXI On The Watch
AVGR Working Towards Vision, MRNS On Track, CCXI On The Watch

Marinus Pharmaceuticals (MRNS) Falls: Stock Goes Down 5.3% - Tale of the Tape
Marinus Pharmaceuticals, Inc. ( MRNS ) saw a big move last session, as the company's shares fell by 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a

Marinus (MRNS) Shows Strength: Stock Moves 8.8% Higher - Tale of the Tape
Marinus Pharmaceuticals, Inc. ( MRNS ) was a big mover last session with its shares rising nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.

Epilepsy device maker NeuroSigma sets terms for $50 million IPO
NeuroSigma, which develops electrical devices used to treat drug resistant epilepsy and depression, announced terms for its IPO on Monday. The Los Angeles, CA based company plans to raise $50 million by offering 3.6 million shares at a price

Epilepsy device maker NeuroSigma files for a $50 million IPO
NeuroSigma, which develops electrical devices used to treat drug resistant epilepsy and depression, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The company is in pivotal trials to

Marinus Pharmaceuticals prices IPO at $8, well below the $12-$14 range
Marinus Pharmaceuticals, an early stage biotech developing an add on therapy for epilepsy, raised $45 million by offering 5.6 million shares at $8, well below the $12 $14 range. Marinus Pharmaceuticals will list on the NASDAQ under

Epilepsy biotech Marinus Pharmaceuticals sets terms for $52 million IPO
Marinus Pharmaceuticals, a clinical stage biotech developing an add on therapy for adults with epilepsy, announced terms for its IPO on Friday. The New Haven, CT based company plans to raise $52 million by offering 4.0 million

Biotech Sage Therapeutics files for a $69 million IPO to fund treatments for deadly seizures
Sage Therapeutics, which is developing treatments for life threatening seizures, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering. Each year, an estimated 30,000 patients die of status epilepticus,